CK-3773274
( DrugBank: - / KEGG DRUG: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 58 | Hypertrophic cardiomyopathy | 16 |
58. Hypertrophic cardiomyopathy
Clinical trials : 126 / Drugs : 135 - (DrugBank : 42) / Drug target genes : 46 - Drug target pathways : 162
Showing 1 to 10 of 16 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-003571-17-DK (EUCTR) | 21/12/202220221221 | 31/10/202220221031 | This study is performed to collect long term safety and tolerability of aficamten (CK-3773274) on patients with symptomatic hypertrophic cardiomyopathy (HCM) This study is performed to collect long term safety and tolerability of aficamten (CK-3773274) on pa ... | An Open-Label Study of CK-3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM). | symptomatic hypertrophic cardiomyopathy (HCM) MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] symptomatic hypertrophic cardiomyopathy (HCM) MedDRA version: 20.0;Level: PT;Classification code 100 ... | Product Name: Aficamten Product Code: CK-3773274 INN or Proposed INN: Aficamten Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Name: Aficamten Product Code: CK-3773274 INN or Proposed INN: Aficamten Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Name: Aficamten Product Code: CK-3773274 INN or Proposed INN: Aficamten Other descriptive name: ... | Cytokinetics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 2 | United States;Portugal;Czechia;Spain;Israel;Italy;United Kingdom;France;Hungary;Poland;Denmark;Netherlands;Germany United States;Portugal;Czechia;Spain;Israel;Italy;United Kingdom;France;Hungary;Poland;Denmark;Nethe ... | ||
| 2 | EUCTR2021-003536-92-PL (EUCTR) | 30/05/202220220530 | 20/04/202220220420 | A Phase 3 trial to measure how safe and effective CK-3773274 is in Adults with obstructive hypertrophic cardiomyopathy (oHCM) A Phase 3 trial to measure how safe and effective CK-3773274is in Adults with obstructive hypertroph ... | A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy ... | obstructive hypertrophic cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] obstructive hypertrophic cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10 ... | Product Name: aficamten Product Code: CK-3773274 INN or Proposed INN: aficamten Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Name: aficamten Product Code: CK-3773274 INN or Proposed INN: aficamten Other descriptive name: ... | Cytokinetics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 270 | Phase 3 | United States;Portugal;Czechia;Spain;Israel;United Kingdom;Italy;France;Hungary;Poland;Denmark;Netherlands;Germany;China United States;Portugal;Czechia;Spain;Israel;United Kingdom;Italy;France;Hungary;Poland;Denmark;Nethe ... | ||
| 3 | EUCTR2021-003536-92-HU (EUCTR) | 09/05/202220220509 | 23/02/202220220223 | A Phase 3 trial to measure how safe and effective CK3773274 is in Adults with obstructive hypertrophic cardiomyopathy (oHCM) A Phase 3 trial to measure how safe and effective CK3773274 is in Adults with obstructive hypertroph ... | A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy ... | obstructive hypertrophic cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] obstructive hypertrophic cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10 ... | Product Name: aficamten Product Code: CK-3773274 INN or Proposed INN: aficamten Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Name: aficamten Product Code: CK-3773274 INN or Proposed INN: aficamten Other descriptive name: ... | Cytokinetics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 270 | Phase 3 | United States;Portugal;Czechia;Spain;Israel;Italy;United Kingdom;France;Hungary;Poland;Denmark;Germany;Netherlands;China United States;Portugal;Czechia;Spain;Israel;Italy;United Kingdom;France;Hungary;Poland;Denmark;Germa ... | ||
| 4 | EUCTR2021-003536-92-ES (EUCTR) | 28/04/202220220428 | 11/03/202220220311 | A Phase 3 trial to measure how safe and effective CK3773274 is in Adults with obstructive hypertrophic cardiomyopathy (oHCM) A Phase 3 trial to measure how safe and effective CK3773274 is in Adults with obstructive hypertroph ... | A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy ... | obstructive hypertrophic cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] obstructive hypertrophic cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10 ... | Product Name: aficamten Product Code: CK-3773274 INN or Proposed INN: aficamten Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Name: aficamten Product Code: CK-3773274 INN or Proposed INN: aficamten Other descriptive name: ... | Cytokinetics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 270 | Phase 3 | United States;Portugal;Czechia;Spain;Israel;United Kingdom;Italy;France;Hungary;Poland;Denmark;Germany;Netherlands;China United States;Portugal;Czechia;Spain;Israel;United Kingdom;Italy;France;Hungary;Poland;Denmark;Germa ... | ||
| 5 | EUCTR2021-003536-92-DK (EUCTR) | 08/04/202220220408 | 09/03/202220220309 | A Phase 3 trial to measure how safe and effective CK3773274 is in Adults with obstructive hypertrophic cardiomyopathy (oHCM) A Phase 3 trial to measure how safe and effective CK3773274 is in Adults with obstructive hypertroph ... | A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy ... | obstructive hypertrophic cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] obstructive hypertrophic cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10 ... | Product Name: aficamten Product Code: CK-3773274 INN or Proposed INN: aficamten Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Name: aficamten Product Code: CK-3773274 INN or Proposed INN: aficamten Other descriptive name: ... | Cytokinetics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 270 | Phase 3 | United States;Portugal;Czechia;Spain;Israel;Italy;United Kingdom;France;Hungary;Poland;Denmark;Germany;Netherlands;China United States;Portugal;Czechia;Spain;Israel;Italy;United Kingdom;France;Hungary;Poland;Denmark;Germa ... | ||
| 6 | NCT05186818 (ClinicalTrials.gov) | February 1, 202220220201 | 23/12/202120211223 | CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Peri ... | A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy ... | Obstructive Hypertrophic Cardiomyopathy (oHCM) | Drug: CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg);Drug: Placebo to match CK-3773274 | Cytokinetics | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | Recruiting | 18 Years | 85 Years | All | 270 | Phase 3 | United States;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom United States;China;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal; ... |
| 7 | EUCTR2020-003571-17-IT (EUCTR) | 30/11/202120211130 | 02/09/202120210902 | An Open-Label Study of CK3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM) and Left Ventricular Outflow Tract Obstruction An Open-Label Study of CK3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM) an ... | An Open-Label Study of CK3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM) and Left Ventricular Outflow Tract Obstruction - na An Open-Label Study of CK3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM) an ... | Obstructive Hypertrophic Cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Obstructive Hypertrophic Cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10 ... | Product Name: n/a Product Code: [CK-3773274] INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Name: n/a Product Code: [CK-3773274] INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1HPYRAZOLE-4-CARBOXAMIDE Product Name: n/a Product Code: [CK-3773274] INN or Proposed INN: CK-3773274 Other descriptive name: (R ... | CYTOKINETICS, INC. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 54 | Phase 2 | United States;Spain;Italy | ||
| 8 | EUCTR2020-003571-17-ES (EUCTR) | 11/08/202120210811 | 14/07/202120210714 | This study is being performed to collect long-term safety and tolerability data of CK-3773274 on patients with obstructive hypertrophic cardiomyopathy (oHCM). This study is being performed to collect long-term safety and tolerability data of CK-3773274on pati ... | An Open-Label Study of CK-3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM) and Left Ventricular Outflow Tract Obstruction. An Open-Label Study of CK-3773274for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM) and ... | obstructive hypertrophic cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] obstructive hypertrophic cardiomyopathy (oHCM) MedDRA version: 20.0;Level: PT;Classification code 10 ... | Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2 ... | Cytokinetics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 54 | Phase 2 | United States;Spain;Italy | ||
| 9 | NCT04848506 (ClinicalTrials.gov) | May 6, 202120210506 | 9/4/202120210409 | CY 6022 is an Open Label Study to Collect Long-term Safety and Tolerability Data for Aficamten (CK-3773274) CY 6022 is an Open Label Study to Collect Long-term Safety and Tolerability Data for Aficamten (CK-3 ... | An Open-Label Study of CK-3773274 for Patients With Symptomatic Hypertrophic Cardiomyopathy (HCM) | Symptomatic Hypertrophic Cardiomyopathy (HCM) | Drug: CK-3773274 (5 - 20 mg) | Cytokinetics | NULL | Enrolling by invitation | 18 Years | 85 Years | All | 300 | Phase 2 | Italy;United States;Poland;Spain |
| 10 | NCT04783766 (ClinicalTrials.gov) | April 10, 202120210410 | 3/3/202120210303 | Safety, Tolerability and Pharmacokinetics Study of CK-3773274 | A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CK-3773274 in Healthy Chinese Subjects A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability a ... | Obstructive Hypertrophic Cardiomyopathy;Healthy Adult Subjects | Drug: CK-3773274;Drug: Placebo | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | Cytokinetics | Completed | 18 Years | 45 Years | All | 28 | Phase 1 | China |